Intra-abdominal anaerobic infections: Bacteriology and therapeutic potential of newer antimicrobial carbapenem, fluoroquinolone, and desfluoroquinolone therapeutic agentsGOLDSTEIN, Ellie J. C.Clinical infectious diseases. 2002, Vol 35, pp S106-S111, issn 1058-4838, SUP1Conference Paper

Reproducibility of broth microdilution and comparison to agar dilution for testing CB-183,315 against clinical isolates of Clostridium difficileCITRON, Diane M; GOLDSTEIN, Ellie J. C.Diagnostic microbiology and infectious disease. 2011, Vol 70, Num 4, pp 554-556, issn 0732-8893, 3 p.Article

2001: An Anaerobe Odyssey: A Celebration of Dr. Sydney M. Finegold's 80th BirhtdayCITRON, Diane M; GOLDSTEIN, Ellie J. C.Clinical infectious diseases. 2002, Vol 35, issn 1058-4838, 138 p., SUP1Conference Proceedings

Moxifloxacin: one a journey toward improving antimicrobial therapyMEYER, Richard D; GOLDSTEIN, Ellie J. C.Clinical infectious diseases. 2001, Vol 32, issn 1058-4838, 81 p., SUP1Serial Issue

Microbiology of Animal Bite Wound InfectionsABRAHAMIAN, Fredrick M; GOLDSTEIN, Ellie J. C.Clinical microbiology reviews (Print). 2011, Vol 24, Num 2, issn 0893-8512, 225, 231-246 [17 p.]Article

Widespread use of fluoroquinolones versus emerging resistance in pneumococciGOLDSTEIN, Ellie J. C; GARABEDIAN-RUFFALO, Susan M.Clinical infectious diseases. 2002, Vol 35, Num 12, pp 1505-1511, issn 1058-4838, 7 p.Article

New Fluoroquinolones and Anaerobic InfectionsGOLDSTEIN, Ellie J. C; UENO, Kazue.Clinical infectious diseases. 1996, Vol 23, issn 1058-4838, 108 p., SUP1Conference Proceedings

Activity of a novel carbapenem, doripenem, against anaerobic pathogensGOLDSTEIN, Ellie J. C; CITRON, Diane M.Diagnostic microbiology and infectious disease. 2009, Vol 63, Num 4, pp 447-454, issn 0732-8893, 8 p.Article

Fluoroquinolones and anaerobesSTEIN, Gary E; GOLDSTEIN, Ellie J. C.Clinical infectious diseases. 2006, Vol 42, Num 11, pp 1598-1607, issn 1058-4838, 10 p.Article

North American congress on anaerobic bacteria and anaerobic infectionsFINEGOLD, Sydney M; GOLDSTEIN, Ellie J. C.Clinical infectious diseases. 1993, Vol 16, issn 1058-4838, SUP4Conference Proceedings

Evolution of anaerobe susceptibility testing in the United StatesHECHT, David W.Clinical infectious diseases. 2002, Vol 35, pp S28-S35, issn 1058-4838, SUP1Conference Paper

Mechanisms responsible for cross-resistance and dichotomous resistance among the quinolonesSANDERS, Christine C.Clinical infectious diseases. 2001, Vol 32, pp S1-S8, issn 1058-4838, SUP1Article

Mechanisms of action of antimicrobials : Focus on fluoroquinolonesHOOPER, David C.Clinical infectious diseases. 2001, Vol 32, pp S9-S15, issn 1058-4838, SUP1Article

Clinical perspectives on new antimicrobials : Focus on fluoroquinolonesTALAN, David A.Clinical infectious diseases. 2001, Vol 32, pp S64-S71, issn 1058-4838, SUP1Article

A new potent β-lactamase inhibitor, BRL 42715, with inherent activity against Bacteroides fragilis group strainsALDRIDGE, K. E.Clinical infectious diseases. 1993, Vol 16, pp S335-S338, issn 1058-4838, SUP4Conference Paper

A century of anaerobes : a look backward and a call to armsFINEGOLD, S. M.Clinical infectious diseases. 1993, Vol 16, pp S453-S457, issn 1058-4838, SUP4Conference Paper

Anaerobic bacterial infections of the lung and pleural spaceBARTLETT, J. G.Clinical infectious diseases. 1993, Vol 16, pp S248-S255, issn 1058-4838, SUP4Conference Paper

Update on the taxonomy and clinical aspects of the genus FusobacteriumCITRON, Diane M.Clinical infectious diseases. 2002, Vol 35, pp S22-S27, issn 1058-4838, SUP1Conference Paper

Bacterial mediators in periodontal diseaseLOESCHE, W. J.Clinical infectious diseases. 1993, Vol 16, pp S203-S210, issn 1058-4838, SUP4Conference Paper

Susceptibility of anaerobic bacteria to β-lactam antibiotics in the United StatesJOHNSON, C. C.Clinical infectious diseases. 1993, Vol 16, pp S371-S376, issn 1058-4838, SUP4Conference Paper

The anaerobic microflora of the human bodyHENTGES, D. J.Clinical infectious diseases. 1993, Vol 16, pp S175-S180, issn 1058-4838, SUP4Conference Paper

Comparative In Vitro Activities of SMT19969, a New Antimicrobial Agent, against 162 Strains from 35 Less Frequently Recovered Intestinal Clostridium Species: Implications for Clostridium difficile RecurrenceGOLDSTEIN, Ellie J. C; CITRON, Diane M; TYRRELL, Kerin L et al.Antimicrobial agents and chemotherapy. 2014, Vol 58, Num 2, pp 1187-1191, issn 0066-4804, 5 p.Article

Comparative in vitro and in vivo activity of the C-8 methoxy quinolone moxifloxacin and the C-8 chlorine quinolone BAY y 3118DALHOFF, Axel.Clinical infectious diseases. 2001, Vol 32, pp S16-S21, issn 1058-4838, SUP1Article

Pharmacodynamics of moxifloxacin and levofloxacin against Staphylococcus aureus and Staphylococcus epidermidis in an in vitro pharmacodynamic modelLISTER, Philip D.Clinical infectious diseases. 2001, Vol 32, pp S33-S38, issn 1058-4838, SUP1Article

Anaerobic bacteremiaGOLDSTEIN, E. J. C.Clinical infectious diseases. 1996, Vol 23, pp S97-S101, issn 1058-4838, SUP1Conference Paper